Shagun Misra

Shagun Misra

Auto-generated profile, based on publicly available information

Shagun Misra

Department of Radiotherapy, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
DKDivya Khosla
Divya Khosla
SMShagun Misra
Shagun Misra
PCPek Lim Chu
Pek Lim Chu
PGPeiyong Guan
Peiyong Guan
RNRitambhra Nada
Ritambhra Nada
JHJing Han Hong
Jing Han Hong
Cholangiocarcinomas (CCA) pose a complex challenge in oncology due to diverse etiologies, necessitating tailored therapeutic approaches. This review discusses the risk factors, molecular pathology, and current therapeutic options for CCA and explores the emerging strategies encompassing targeted therapies, immunotherapy, novel compounds from natural sources, and modulation of gut microbiota. CCA are driven by an intricate landscape of genetic mutations, epigenetic dysregulation, and post-transcriptional modification, which differs based on geography (e.g., for liver fluke versus non-liver fluke-driven CCA) and exposure to environmental carcinogens (e.g., exposure to aristolochic acid). Liquid biopsy, including circulating cell-free DNA, is a potential diagnostic tool for CCA, which warrants further investigations. Currently, surgical resection is the primary curative treatment for CCA despite the technical challenges. Adjuvant chemotherapy, including cisplatin and gemcitabine, is standard for advanced, unresectable, or recurrent CCA. Second-line therapy options, such as FOLFOX (oxaliplatin and 5-FU), and the significance of radiation therapy in adjuvant, neoadjuvant, and palliative settings are also discussed. This review underscores the need for personalized therapies and demonstrates the shift towards precision medicine in CCA treatment. The development of targeted therapies, including FDA-approved drugs inhibiting FGFR2 gene fusions and IDH1 mutations, is of major research focus. Investigations into immune checkpoint inhibitors have also revealed potential clinical benefits, although improvements in survival remain elusive, especially across patient demographics. Novel compounds from natural sources exhibit anti-CCA activity, while microbiota dysbiosis emerges as a potential contributor to CCA progression, necessitating further exploration of their direct impact and mechanisms through in-depth research and clinical studies. In the future, extensive translational research efforts are imperative to bridge existing gaps and optimize therapeutic strategies to improve therapeutic outcomes for this complex malignancy.

1 March 2021 in Journal of Medical Imaging and Radiation Sciences
Verified
Journal Article
Closed access
SMShagun Misra
Shagun Misra
AMAshutosh Mishra
Ashutosh Mishra
PLPunita Lal
Punita Lal
RSResham Srivastava
Resham Srivastava
MVMrinalani Verma
Mrinalani Verma
KDKoilpillai Joseph Maria Das
Koilpillai Joseph Maria Das

8 May 2020 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
WSWei Shi
Wei Shi
SMShagun Misra
Shagun Misra
Madeline LiMadeline Li
Madeline Li
JSJie Su
Jie Su
LCLisa P Chong
Lisa P Chong
FLFei-Fei Liu
Fei-Fei Liu
Fatigue and insomnia are common symptoms experienced by breast cancer patients undergoing adjuvant radiation therapy (RT), yet the underlying mechanisms of these symptoms are unclear. In particular, the roles of hematopoietic stem cells (HSCs) and inflammatory cytokines remain to be elucidated. Breast cancer patients (n = 147) completed questionnaires to longitudinally assess symptoms before, during, and after adjuvant RT. Phlebotomies were performed prior to RT, at the second and fifth treatment fractions, end of treatment (EOT), and 1 month after completing RT, assessing for CD34+, CD45+, full hematology, and 17 inflammatory cytokines. The associations between symptoms and all biomarkers were evaluated. All statistical tests were 2-sided. General fatigue and insomnia worsened with RT, with peak levels observed at EOT, which remained statistically significant even after controlling for anxiety and depression (P < .05 for all). CD34+, CD45+, white blood cell, and lymphocyte counts decreased, with the lowest levels also observed at EOT (P < .001). Fatigue and insomnia were associated with changes in both interferon γ-induced protein 10 (IP-10) - (P = .03 and P = .01, respectively) and tumor necrosis factor receptor II (TNF-RII) (P = .02 and P = .006, respectively), while mental fatigue was associated with increased matrix metalloproteinases-2 (MMP-2) levels (P = .03). Patients who received prior chemotherapy demonstrated statistically significantly greater severity in all symptoms, with lower baseline HSC levels. This is the first longitudinal study to examine linkages between symptoms, HSCs, and cytokines, demonstrating that fatigue and insomnia shared associations with increasing serum levels of IP-10 and TNF-RII, and mental fatigue was associated with increasing serum levels of MMP-2. Our findings highlight opportunities for further research into mechanisms and potential interventions for these symptoms.

1 March 2022 in Precision Cancer Medicine
Verified
Journal Article
Open access
PDF file
FAFares Azoury
Fares Azoury
SMShagun Misra
Shagun Misra
Aisling BarryAisling Barry
Aisling Barry
JHJoelle Helou
Joelle Helou
Role of radiation therapy in triple negative breast cancer: current state and future directions—a narrative review Fares Azoury, Shagun Misra, Aisling Barry, Joelle Helou

1 January 2018 in Cancer Treatment and Research Communications
Verified
Journal Article
Closed access
SMShagun Misra
Shagun Misra
PLPunita Lal
Punita Lal
SESaibish Kumar Ep
Saibish Kumar Ep
NRNeeraj Rastogi
Neeraj Rastogi
ATAnu Tiwari
Anu Tiwari
SKShaleen Kumar
Shaleen Kumar

14 October 2021 in The Egyptian Journal of Otolaryngology
Verified
Journal Article
Open access
PDF file
SPSidharth Pant
Sidharth Pant
PLPunita Lal
Punita Lal
SMShagun Misra
Shagun Misra
PGPiyush Gupta
Piyush Gupta
KDK. J. Maria Das
K. J. Maria Das
SKShaleen Kumar
Shaleen Kumar
The purpose of the study was to evaluate survival outcomes in post-operative oral tongue cancer patients undergoing adjuvant radiotherapy (RT) at a tertiary cancer care center and to critically review the impact of various clinical-pathological factors on recurrence and survival. Demographic factors, stage of all the histology proven oral tongue cancer, and treatment details were documented. Overall survival (OS) and recurrence-free survival (RFS) were analyzed along with the potential prognostic factors affecting outcome. One hundred forty-four post-operative oral tongue cancer patients referred to our department for adjuvant treatment were evaluated. Median age at presentation was 45 years. Forty-seven patients had pathological early stage disease (stages I and II) and 95 had locally advanced (stages III and IV) disease while post-op details were not present in 2 patients. At a median follow-up of 87 months (60–124) of alive patients, the median RFS for entire cohort was 62 months while median OS was 74 months respectively. Age, perineural invasion (PNI), and grade of the tumor emerged as independent prognostic factors for OS and RFS. Among patients with early stage disease, depth of invasion (DOI), age, and PNI were found as independent prognostic factors for RFS and OS. In locally advanced disease, higher grade, age, and PNI independently impacted the respective survival end points. Age (> 45 years), higher grade, and presence of PNI showed inferior survival outcomes across the sub-groups (early versus locally advanced disease). This may warrant adjuvant treatment intensification. DOI > 10 mm was particularly found to worsen survival in early node negative SCC oral tongue patients.